Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tianjin Development Holdings ( (HK:0882) ) just unveiled an announcement.
Tianjin Development Holdings, through its subsidiary Lisheng Pharmaceutical, plans to form a private equity fund with a total capital commitment of RMB500 million, focusing on health and biotechnology sectors in the PRC. Lisheng Pharmaceutical will contribute approximately 34.75% of the fund’s capital. This potential transaction, if realized, will be a discloseable and connected transaction subject to shareholder approval and regulatory requirements. The fund’s formation aims to strengthen the company’s position in the health and biotechnology sectors, potentially impacting its market presence and stakeholder interests.
More about Tianjin Development Holdings
Tianjin Development Holdings operates in the pharmaceutical industry through its subsidiary Lisheng Pharmaceutical. The company focuses on health and biotechnology sectors in the People’s Republic of China (PRC).
Average Trading Volume: 1,107,697
Current Market Cap: HK$3.06B
Find detailed analytics on 0882 stock on TipRanks’ Stock Analysis page.